According to Fortune Business Insights, the global breast biopsy devices market size was valued at USD 1.51 billion in 2025. The market is projected to grow from USD 1.59 billion in 2026 to USD 2.64 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 6.5% during the forecast period. North America dominated the global market in 2025, supported by advanced healthcare infrastructure and increasing demand for breast cancer diagnostics.
Breast biopsy devices are medical instruments used to collect tissue samples from suspicious breast lesions to determine whether they are benign or malignant. These devices play an essential role in breast cancer diagnosis, clinical decision-making, and treatment planning. Common technologies include core needle biopsy systems, vacuum-assisted biopsy systems, fine needle aspiration systems, and specialized biopsy needles.
The increasing incidence of breast cancer, growing awareness of early diagnosis, and expansion of breast cancer screening programs are supporting market growth. Furthermore, technological advancements in image-guided procedures and minimally invasive diagnostic techniques are encouraging healthcare providers to adopt advanced biopsy devices.
Market Size and Forecast
- 2025 Market Size: USD 1.51 billion
- 2026 Market Size: USD 1.59 billion
- 2034 Forecast Market Size: USD 2.64 billion
- CAGR (2026–2034): 6.5%
The market is expected to expand as healthcare providers prioritize accurate diagnosis, improved patient comfort, and efficient breast cancer screening and monitoring. Investments in innovative biopsy technologies and advanced imaging systems are also expected to create new growth opportunities.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/breast-biopsy-devices-market-115264
Key Market Growth Drivers
Rising Incidence of Breast Cancer
The increasing burden of breast cancer worldwide is a major factor driving demand for breast biopsy devices. Early and accurate diagnosis is essential for determining the nature of suspicious breast lesions and selecting appropriate treatment strategies. Biopsy procedures allow clinicians to examine tissue samples and establish definitive diagnoses.
Growing awareness of breast health and expanding screening initiatives are also encouraging patients to seek diagnostic evaluations. As more suspicious lesions are identified through mammography and other imaging techniques, demand for reliable biopsy procedures is expected to increase.
Growing Preference for Minimally Invasive Procedures
Minimally invasive biopsy techniques are gaining popularity because they generally require smaller incisions, reduce procedural discomfort, and can often be performed in outpatient settings. Core needle biopsy and vacuum-assisted biopsy systems enable clinicians to obtain tissue samples while minimizing disruption to surrounding tissues.
These techniques can improve procedural efficiency and support faster diagnostic decision-making. Continued improvements in needle design, sample collection, and tissue handling are further contributing to their adoption.
Technological Advancements in Image-Guided Biopsy
Innovations in ultrasound-guided, mammography-guided, and MRI-guided biopsy systems are improving the targeting of suspicious breast lesions. These technologies help clinicians locate abnormalities that may be difficult to detect or access through conventional methods.
Manufacturers are also developing improved biopsy platforms, advanced imaging software, and enhanced specimen handling solutions. Such developments are expected to strengthen diagnostic accuracy and support the broader adoption of breast biopsy devices.
Market Segmentation
According to Fortune Business Insights, the market is segmented by product type, guidance system, application, and end-user.
By Product Type: The market includes core needle biopsy (CNB) systems, vacuum-assisted biopsy (VAB) systems, fine needle aspiration (FNA) systems, biopsy needles, specimen handling systems, and others. Core needle biopsy systems are anticipated to hold the largest market share because they provide tissue samples suitable for detailed pathological examination. Vacuum-assisted biopsy systems are also gaining attention because they can collect multiple tissue samples through a single insertion.
By Guidance System: Major categories include ultrasound-guided biopsy, MRI-guided biopsy, mammography-guided biopsy, and others. Ultrasound-guided biopsy held the dominant position in 2025, supported by its accessibility, cost-effectiveness, and real-time imaging capabilities. MRI-guided biopsy is expected to experience notable growth because it helps target suspicious abnormalities identified through magnetic resonance imaging.
By Application: The market includes screening, diagnostics, and therapy response monitoring. The diagnostics segment is anticipated to maintain a leading position because biopsy procedures are essential for confirming suspected breast cancer. Therapy response monitoring also presents growth opportunities as clinicians increasingly emphasize personalized treatment and follow-up assessment.
By End-User: Hospitals, specialty clinics, diagnostic centers, and other healthcare facilities represent the principal end-users. Hospitals dominated the market, accounting for 48.1% of the share in 2025, supported by high diagnostic procedure volumes and access to advanced medical equipment.
Regional Market Insights
North America
North America dominated the global breast biopsy devices market, generating USD 0.62 billion in revenue in 2025. Strong healthcare infrastructure, increasing breast cancer diagnostic rates, and investments in medical technology support regional growth. The U.S. market is projected to reach approximately USD 0.56 billion in 2026.
Europe
Europe represents a significant market, supported by established healthcare systems, organized screening initiatives, and increasing access to diagnostic services. The region is projected to reach USD 0.43 billion in 2026. Government-supported breast cancer awareness programs and improvements in diagnostic infrastructure are contributing to market development.
Asia Pacific
Asia Pacific is expected to reach USD 0.36 billion in 2026. Increasing awareness of breast cancer, expanding healthcare infrastructure, and growing demand for advanced diagnostic procedures are supporting regional expansion. China, India, and Japan are important markets for breast biopsy devices.
Key Market Challenges
The breast biopsy devices market faces challenges associated with reimbursement uncertainties, high equipment costs, and the need for specialized clinical expertise. Limited reimbursement clarity for newer biopsy techniques may discourage healthcare facilities from investing in advanced systems.
Additionally, increasing diagnostic volumes can place pressure on radiology departments and pathology laboratories, potentially extending reporting timelines. Manufacturers and healthcare providers must address these challenges through cost-effective technologies, improved workflows, and efficient sample processing.
Competitive Landscape
The global breast biopsy devices market includes established medical device manufacturers and specialized diagnostic technology companies. Key players identified by Fortune Business Insights include Hologic, Inc., BD, Danaher Corporation, Argon Medical Devices, Inc., Merit Medical Systems, Inc., Fujifilm Corporation, GE HealthCare, QIAGEN, Cook, and Devicor Medical Products, Inc.
Companies are focusing on product innovation, strategic collaborations, portfolio expansion, and improved imaging compatibility to strengthen their competitive positions. Developments in vacuum-assisted biopsy, advanced needle systems, and image-guided procedures are expected to support future industry growth.
Conclusion
The global breast biopsy devices market is projected to grow from USD 1.51 billion in 2025 to USD 2.64 billion by 2034. Rising breast cancer incidence, increased screening awareness, and advancements in minimally invasive diagnostic technologies are expected to drive market expansion. Although reimbursement uncertainties and diagnostic workflow challenges remain, continued innovation and wider access to advanced biopsy procedures are likely to create significant opportunities for the industry.
Comments